Detalhe da pesquisa
1.
RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature
; 526(7574): 583-6, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26466569
2.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
N Engl J Med
; 373(5): 428-37, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26222558
3.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Nature
; 467(7315): 596-9, 2010 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20823850
4.
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.
Proc Natl Acad Sci U S A
; 110(14): 5689-94, 2013 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23493555
5.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
Proc Natl Acad Sci U S A
; 105(8): 3041-6, 2008 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18287029
6.
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
JAMA Oncol
; 7(9): 1343-1350, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34236401
7.
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.
JCI Insight
; 3(14)2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30046005
8.
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Cancer Discov
; 8(4): 458-477, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386193
9.
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Cancer Discov
; 5(6): 668-79, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25847190